Asia Pacific
Refine Search
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Zhongshan-based biopharma company Akeso will await the verdict of the Chinese medicines regulator on a penpulimab-based combo therapy. 22 November 2024
Pharmaceutical
Shanghai-based Zai Lab and New York’s Pfizer are to work together on the commercialization of Xacduro (sulbactam-durlobactam) in China. 22 November 2024
Biotechnology
Hong Kong-based Sino Biopharm has signed an equity investment and strategic collaboration agreement with LaNova Medicines, advancing its oncology focus. 22 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Biotechnology
Shanghai-based Junshi Biosciences has received UK regulatory approval for Loqtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). 18 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based clinical-stage biotech LaNova Medicines, bringing the US pharma giant into the newly attractive PD-1/VEGF bispecific antibody space. 15 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Generics
Japanese drug major Chugai Pharmaceutical announced that, along with majority owner Roche and its biotech subsidiary Genentech (collectively “the companies”) have entered into a settlement agreement with Fresenius Kabi USA, on August 5, 2022 relating to the patent lawsuit filed by the companies on March 19, 2020. 9 August 2022
Biotechnology
Following positive results in a Phase III study of fruquintinib, Hutchmed's shares were on the way up on Monday. 8 August 2022
Biotechnology
Preliminary results from the Savannah Phase II trial showed that Tagrisso (osimertinib) plus savolitinib demonstrated an objective response rate of almost 50% in patients. 8 August 2022
Biotechnology
Sino-American biotech BeiGene saw its shares close up more than 12% at 112.05 renminbi on Friday, after it reported financial results for the second quarter of 2022, recent business highlights, and anticipated upcoming milestones. 8 August 2022
Biotechnology
Japanese drugmaker Maruho has launched the anti-interleukin (IL)-31 receptor A humanized monoclonal antibody Mitchga (nemolizumab [genetical recombination]) subcutaneous Injection 60mg syringes for the treatment of itching associated with atopic dermatitis (only when existing treatment is insufficiently effective). 8 August 2022
Biotechnology
Shares of Chinese contract research, development and manufacturing organization (CRDMO) WuXi Biologics rose more than 5% yesterday, after the Chinese vaccine maker said it is partnering with AstraZeneca to produce the UK pharma major’s COVID-19 preventive drug, that was approved by Chinese regulatory authorities last month, according to a report by Yicai Global. 5 August 2022
Biotechnology
French pharma major Sanofi and China’s Innovent Biologics have signed a collaboration to bring innovative medicines to patients in China with difficult-to-treat cancers. 5 August 2022
Biotechnology
US pharma giant Merck & Co and Japan’s Eisai today announced that the Phase III LEAP-002 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, plus Lenvima (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, versus Lenvima monotherapy did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). 3 August 2022
Pharmaceutical
Shares of Sosei Group were up nearly 5% at 1,500 yen today, as it announced a lucrative deal with US pharma major AbbVie. 2 August 2022
Biotechnology
USA-based GreenLight Biosciences, a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible, saw its shares close up almost 10% at $2.33 yesterday, after it announced the successful completion of the first commercial-scale engineering run for the mRNA production partnership with South Korean contract development and manufacturing organization (CDMO), Samsung Biologics. 2 August 2022
Biotechnology
GluBio Therapeutics, a Sino-American biotech developing novel targeted protein degradation (TPD) drugs, has completed a Series A+ financing of $22 million. 2 August 2022
Biotechnology
USA-based Elevation Oncology today announced that it has entered into an exclusive license agreement with CSPC Megalith Biopharmaceutical, a subsidiary of China’s CSPC Pharmaceutical Group to develop and commercialize EO-3021 (SYSA1801), a differentiated, clinical stage antibody drug conjugate (ADC) targeting Claudin18.2, in all global territories outside Greater China. 28 July 2022
Biotechnology
Brii Biosciences has announced new live virus data confirming that the amubarvimab/romlusevimab combination, a long-acting COVID-19 monoclonal antibody therapy, retains neutralizing activity against the Omicron BA.4/5 and BA.2.12.1 SARS-CoV-2 subvariants. 28 July 2022
Biotechnology
Chinese RNA company Rona Therapeutics has announced a deal with French pharma major Sanofi. 25 July 2022
Generics
Medicines Australia and the Generic and Biosimilars Medicines Association have shared concerns about medicine shortages that are impacting patients in the country. 22 July 2022
Pharmaceutical
Japan’s largest drugmaker Takeda has announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase III clinical trial evaluating Hyqvia (immune globulin Infusion 10% (human) with recombinant human hyaluronidase) for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint. 22 July 2022
Pharmaceutical
Japanese drugmaker Ono Pharmaceutical has announced the establishment and start of an investment business of Ono Digital health Investment, GK (ODhI) as a corporate venture capital (CVC) that invests in venture companies in the field of healthcare, other than the ethical pharmaceutical drug-related field. 20 July 2022
Biotechnology
Chinese contract research, development and manufacturing organization (CRDMO) WuXi Biologics has announced a 10-year, $1.4 billion investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore. 19 July 2022
Biotechnology
Japanese drugmaker Daiichi Sankyo today announced today that the US Patent and Trademark Office (PTO) has granted Seagen’s request for rehearing of the decision to institute post-grant review, and therefore decided not to proceed with the post-grant review process in which Daiichi Sankyo was contesting the patentability of certain claims within Seagen’s US patent 10,808,039 (the ’039 patent). 19 July 2022
Biotechnology
Chinese biotech firm CStone Pharmaceuticals' is mulling over a potential sale of the business, according to sources cited by Bloomberg. 18 July 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze